Luforbec 200/6 mdi® (formeterol/beclometasone)
Clinical Indication
Treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate
Comments
At the request of the Respiratory Prescribing Group for formulary reasons.
Date of classification
January 2023
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.